ERLEADA DIN 02540185
Health Canada record
| Active ingredient(s) | APALUTAMIDE 240 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L02BB05 APALUTAMIDE |
| Original market date | 01-Nov-2023 |
| Current status date | 01-Nov-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing APALUTAMIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02478374 | ERLEADA | JANSSEN INC | Tablet | APALUTAMIDE 60 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 31363 | 2023-08-02 | Supplement to a New Drug Submission (SNDS) | New strength. |
International API supply for APALUTAMIDE
17 active FDA Drug Master Files.
Request a quote for ERLEADA